Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CAD | P27708 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5683288 | 0.82 | HTT (0.46) | HTTKMT2ACAD | |
| SCHEMBL8974020 | 0.82 | HTT (0.46) | HTTKMT2ACAD | |
| SCHEMBL9201482 | 0.82 | HTT (0.46) | HTTKMT2ACAD | |
| SCHEMBL10101200 | 0.79 | KMT2A (0.53) | KMT2A | |
| SCHEMBL12359033 | 0.71 | — | — | |
| SCHEMBL12956482 | 0.71 | — | — | |
| SCHEMBL23370679 | 0.71 | ITGB3 (0.33) | KMT2A | |
| SCHEMBL22749689 | 0.70 | — | — | |
| SCHEMBL22749694 | 0.70 | — | — | |
| SCHEMBL5324369 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213532-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | KAI PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8680062-B2 | System for delivering therapeutic agents into living cells and cells nuclei | Deliversir Ltd. (IL) | 2014-03-25 | — | — | US | disclosed |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | SEGEV LABORATORIES LIMITED (IL) | 2008-01-03 | — | — | US | disclosed |
| US-20070015818-A1 | Cyclic sulfone containing retroviral protease inhibitors | G.D. Searle & Co. (now G.D. Searle, LLC) (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213532-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | ADM2, SLC7A1, ARG1 | HTT 1251/4885KMT2A 3688/4885CAD 700/4885 |
| US-20070015818-A1 | Cyclic sulfone containing retroviral protease inhibitors | TMPRSS15, TMPRSS11D, MME | HTT 1976/4885KMT2A 1138/4885CAD 2131/4885 |
| US-20080004234-A1 | System for delivering therapeutic agents into living cells and cells nuclei | RCC1, NUMA1, ACIN1 | HTT 1056/4885KMT2A 4420/4885CAD 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.